Zydus Cadila said today that its plasmid DNA vaccine, ZyCoV-D COVID-19, has been established in Phase I clinical trial as safe and well-tolerated. Phase II clinical trials will be conducted by the organization from 6 August 2020. The Phase I trial with ICMR has also been completed for another indigenously covid vaccine developed with Bharat Biotech.
Zydus Cadila said the dose of a vaccine for healthy volunteers was well tolerated in a clinical Phase I trial that began on 15 July 2020. In preclinical toxicity studies, the vaccine had previously been shown to be healthy, immunogenic, and well-tolerated.
In animal trials, Zydus Cadila said that the vaccine was able to produce a high degree of neutralizing antibodies.
Zydus Cadila also said the Phase II analysis is planned to test the vaccine candidate’s humoral and cellular immune response. The virus neutralization test will also monitor the neutralization ability of vaccine-induced antibodies. This will also measure the reliability of the humoral reaction up to six months after the last dose.
More than 100 candidates in various stages of clinical trials are in production globally and more than two dozen are in different phases.
Also approved yesterday was the Oxford vaccine, developed by the Indian Serum Institute, for Phase 2 and 3, which would start at 17 sites in India in a week’s time.
The post Zydus Cadila declares early covid vaccine trial effective, Phase II will begin tomorrow appeared first on Insights Care.
